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Priming of T cells in lymphoid tissues of HIV-infected individuals occurs in the presence of
HIV-1. DC in this milieu activate T cells and disseminate HIV-1 to newly activated T cells, the
outcome of which may have serious implications in the development of optimal antiviral
responses. We investigated the effects of HIV-1 on DC–naı ¨ve T-cell interactions using an
allogeneic in vitro system. Our data demonstrate a dramatic decrease in the primary
expansion of naı ¨ve T cells when cultured with HIV-1-exposed DC. CD4
1 and CD8
1 Tc e l l s
showed enhanced expression of PD-1 and TRAIL, whereas CTLA-4 expression was observed
on CD4
1 T cells. It is worth noting that T cells primed in the presence of HIV-1 suppressed
priming of other naı ¨ve T cells in a contact-dependent manner. We identiﬁed PD-1, CTLA-4,
and TRAIL pathways as responsible for this suppresion, as blocking these negative mole-
cules restored T-cell proliferation to a higher degree. In conclusion, the presence of HIV-1
during DC priming produced cells with inhibitory effects on T-cell activation and prolifera-
tion, i.e. suppressor T cells, a mechanism that could contribute to the enhancement of HIV-1
pathogenesis.
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Introduction
DC are professional APC with the unique capacity to prime naı ¨ve
T cells [1]. Immature DC (IDC) provide a ﬁrst line of defense
against infectious agents, pick up pathogens from tissue and
mucosal sites, and migrate to lymph nodes where these cells
activate speciﬁc naı ¨ve T cells. During migration, factors required
for tissue homing are downregulated and costimulatory mole-
cules, namely MHC class I and II, CD80, CD86, CD40, and CCR7
are upregulated [2]. These events are crucial for efﬁcient antigen
presentation, downstream signaling, and T-cell activation [3].
Mucosal exposure during sexual contact is the primary route of
transmission of HIV-1 and DC subsets lining the genital or rectal
mucosa are among the ﬁrst immune cells to come in contact
with the virus [4]. Viral binding to DC is mediated by interaction with
several surface molecules, e.g. the CD4 receptor, CCR5 and/or
CXCR4, C-type lectins such as DC-SIGN, and the macrophage-
mannose receptor [5]. DC-SIGN binds HIV-1 and enhances infection
in newly activated T cells [5, 6] via formation of infectious synapses
at the DC-T-cell contact zone [7]. The ability of DC to capture HIV-1
and migrate to lymph nodes ensures an environment where there is
constant viral presence, especially at the site of DC priming and T-cell
activation [1].
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partly because the virus has evolved to exploit the normal immune
functions. The majority of infected individuals with high viral loads
have both diminished levels and functionally impaired DC and
CD4
1 T cells [8, 9], which reveals that the presence of high viral
burden exerts negative and deleterious effects on host immune cells.
The effects HIV-1 exerts on DC phenotypes and immune func-
tions have been described in various in vitro experiments [10–14].
Individual HIV-1 proteins, such as nef, vpr, and tat have been
shown to mediate negative effects on immune cells. Nef has been
associated with decreased surface expression of MHC class I, CD80,
and CD86 molecules in infected cells [15, 16]. Furthermore, nef
can upregulate TNF-a and Fas ligand (FasL) expression on DC,
resulting in cytotoxic DC with impaired ability to activate CD8
1
T cells [14]. Vpr downregulates the expression of costimulatory
molecules on DC [9], whereas tat triggers IFN responsive gene
expression in IDC without inducing maturation [11, 12].
Given the opposing effects observed for HIV-1 proteins, the use
of whole virions offers certain advantages when studying the effects
of HIV-1 on immune functions in vitro. To our knowledge, very few
studies have addressed the effects exerted by whole virions on DC
[11, 12, 17–19]. Experiments revealed that the production of IL-10
in cocultures with productively infected IDC impaired T-cell
proliferation [11] and that p24-positive-infected DC failed to
produce IL-12 p70 in response to CD40-ligand activation [19].
Further, infection of plasmacytoid DC induced IFN-a secretion and
was partially responsible for the induction of TRAIL on T cells.
HIV-1-exposed DC induced apoptosis in both uninfected and
infected CD4
1 T cells due to increased sensitivity to the FasL,
TRAIL, TNF-a, and TWEAK receptors [17].
Treg modulate memory T-cell functions in HIV-1-infected
individuals [20, 21] and their depletion could lead to immune
hyperactivation. It is worth noting that chronic immune-hyper-
activation associated with impaired T-cell functions is also seen in
HIV-1 infection, although the underlying mechanisms remain
elusive. Accumulating evidence suggests that CTLA-4 expression
correlate positively with HIV disease progression [22], and that
PD-1 expression on CD4
1 T-cells directly correlates with
increased viral load [23]. Nonetheless, blockade of CTLA-4 or
PD-1 restored and augmented HIV-speciﬁc T-cell functions [22].
Taken together, these studies suggest that failure of T cells to
effectively control HIV-1 infection could largely be attributed to
the elevated expression of inhibitory molecules.
We investigated the effects of HIV-1 on the ability of DC to prime
naı ¨ve CD4
1 and CD8
1 Tc e l l si na nin vitro allogeneic system and
elucidated the mechanisms through which HIV-1 impairs the ability
of DC to prime naı ¨ve T cells. We used infectious HIV-1 (inf-HIV) and
noninf-HIV chemically inactivated with aldrithiol-2 (AT-2 HIV)
virions to determine if productive infection or exposure to virions
alone was sufﬁcient to affect DC function. We found that exposure to
both inf-HIV and AT-2 HIV impaired the ability of DC to prime naı ¨ve
T-cell responses. Interestingly, the T cells primed by DC in the
presence of HIV-1 suppressed subsequent activation of new naı ¨ve
T cells. We also found that the suppression was dependent on cell-to-
cell contact and independent of inhibitory cytokines, i.e. IL-10 and
TGF-b. HIV-1-exposed DC showed no major alterations in CD40,
CD80, or CD86 expression, whereas the primed T cells had increased
expression of proteins known to have a negative impact on T-cell
activation and proliferation, such as CTLA-4, PD-1, TRAIL, and
Foxp3. The upregulation of CTLA-4, PD-1, and TRAIL, and the
signaling events occurring through these receptors appeared to
contribute substantially to T-cell impairment as their blockade fully
restored T-cell proliferation, ﬁtting with the herein described cell-to-
cell contact-dependent mechanism. Our study highlights an impor-
tant aspect of HIV-1 pathogenesis whereby the presence of HIV-1
virions, whether infectious or noninfectious, during the priming of
naı ¨ve T cells by DC could have a detrimental outcome on the
priming event and therefore contributes to T-cell impairment and
immune dysfunctions occurring in vivo in HIV-1-infected individuals.
Results
Phenotypic characterization of DC and T cells
Several studies have examined the effect of HIV-1-exposed human
immature myeloid DC exert on T cells and demonstrated
consequential effects, such as production of chemoattractants,
proliferation inhibitors, and cytotoxic factors [11–13]. Therefore,
we established whether DC exposed to high doses (175–750ng p24
equivalents) of whole inf-HIV or AT-2-HIV (CXCR4-tropic HIV-MN
or CCR5-tropic HIV-1BaL) were impaired in their ability to prime
naı ¨ve T cells. We established an allogeneic primary culture system
consisting of DC and naı ¨ve bulk T cells. Inf-HIV-1 and AT-2 HIV-1
were compared to determine whether productive infection was
required or if viral exposure alone was sufﬁcient to affect the
outcome. The priming consisted of IDC or mature DC (MDC)
(Fig. 1A) cocultured with negatively selected naı ¨ve CD45RA
1
CD62L
1 bulk T cells (Fig. 1B). IDC and MDC were CD14
 and IDC
had no or very low CD83 expression, whereas their mature
counterparts had 80% or higher CD83 expression (Fig. 1A). It is
worth noting that HIV-1 exposure did not affect DC viability as
assessed by Annexin V and Trypan blue exclusion (data not shown).
Some studies have shown induction of maturation in Monocyte-
derived DC (MDDC) after exposure to high amounts of HIV-1 [24],
whereas we and others detected very little or no contribution of
HIV-1 to DC maturation [1, 25] (data not shown). The difference in
outcome could be due to the virus strains used and/or how the DC
were prepared. The T cells displayed a naı ¨ve (CD3
1CD45RA
1)
phenotype and were 90–95% pure. After 7 days of coculture with
DC, majority of CD4
1 and CD8
1 T cells (80–100%) assumed a
memory (CD3
1CD45RO
1)p h e n o t y p e( F i g .1 B ) .
Both inf-HIV and non-inf-HIV impaired the ability of
DC to prime naı ¨ve T cells
High viral loads in HIV-1 infection are implicated in causing DC
and T-cell functional impairment [8, 9]. Hence, we investigated
the in vitro effects HIV-1 has on DC ability to prime T-cell
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or inf-HIV-1 (CCR5- or CXCR4-tropic HIV-1; 175–750ng p24
equivalents/mL: corresponding to 0.5–2MOI) were cocultured
and T-cell proliferation was assessed at different days by CFSE
dilution and/or
3H-Thymidine incorporation. Our experiments
showed that both CXCR4- and CCR5-tropic AT-2 and inf-HIV-
exposed MDC induced less T-cell proliferation as compared with
mock DC (CXCR4: Fig 2A and CCR5: Fig 2B). HIV-1-exposed DC
inhibited T-cell proliferation by as much as 50% compared with
those without HIV-1. Notably, even the lowest HIV-1 dose, i.e.
175ng p24 equivalents/mL, exerted a negative effect on
proliferation (data not shown). Nonetheless, the effects at higher
doses were more pronounced and consistent in the assays. It is
worth noting that these doses do exist in vivo where DC–T cell
interaction occurs, as 100–10000 virions (35–3500pg p24) can
be released in the contact zone [26].
Although we observed a decreasing trend in T-cell proliferation
stimulated by IDC exposed to HIV-1 (Fig. 2A and B), their inherent
decreased capacity to activate T cells and ability to suppress T-cell
responses [27] masked any signiﬁcant inhibition caused by HIV-1
exposure. We also found that CXCR4-tropic HIV-1 pulsed DC
possessed an impaired ability to induce naı ¨ve T-cell proliferation in
only 53% of donors/assays tested with an overall insigniﬁcance
(p40.05) of T-cell suppression when experiments were normalized
together (Fig. 2C). Contrarily, the CCR5-tropic HIV-1 had more
consistent (95% donors) (po0.001) T-cell impairment after
normalization (Fig. 2D). The CXCR4-tropic HIV-1MN showed more
diverse effects, which could be due to the difference in patho-
genicity attributes between the strains tested. Intriguingly, the
CCR5-tropic HIV-1BaL exerted negative effects on mature DC–T
cell cocultures independent of the donor, thereby ensures itself and
the MDC the prime focus of our subsequent investigation.
Presence of HIV-1 during priming gave rise to contact-
dependent suppressor T cells
The diminished proliferation seen for T cells primed by HIV-1-
pulsed mature MDDC could be due to countless factors, e.g.
increased apoptosis or IL-10 production [11]. Therefore, we
examined whether memory T cells primed from naı ¨ve T-cells or
factors secreted in supernatants had any effect on the activation
of other naı ¨ve T-cells. T cells previously primed by mock, AT-2
HIV, and inf-HIV exposed DC or supernatants derived from these
cultures were added to new allogeneic DC–T cell assays and
cultured for 7 days. The addition of T cells previously primed by
DC in the presence of HIV-1 impaired the proliferation of new
naı ¨ve T cells (Fig. 3A and B) that was independent of the DC type
used (immature or mature) to initiate the previous priming but
depended on whether the previously primed T cells exhibited
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Figure 1. Characterization of IDC and mature DC, naı ¨ve, and activated T cells (A) IDC were harvested after 6 days of propagation. In total, 30mg/mL
polyI:C for 24h was added to induce maturation. DC were characterized by staining with PE-mAb against CD14 and CD83. (A) CD14 and CD83
expression on IDC (left panel) and MDC (right panel). (B) Bulk naı ¨ve T cells, negatively selected from PBMC, were immunophenotyped For CD3, CD4,
CD8, and CD45RA expression on day 0 for CD4 and CD8 (upper panel), CD3 and CD45RA (middle panel), and after 8 days of MDC–T-cell coculture for
CD3 and CD45RO (lower panel).
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T-cell proliferation differed between donors from 45 to 80%.
Hence, we showed that the proliferation was signiﬁcantly
impaired in cultures where T cells were previously primed with
AT-2 HIV (Fig. 3B: po0.0001) and inf-HIV-exposed DC (Fig. 3B:
po0.001).
To determine if soluble factors secreted in the initial priming
cultures had an impact on naı ¨ve T-cell activation, we added
culture supernatants from the initial cultures to new priming
cultures. Interestingly, this did not have a negative impact on
naı ¨ve T-cell priming in the new DC–T cell assays (Fig. 3D).
Furthermore, extensive cytokine analysis in culture supernatants
failed to divulge any distinct pattern besides decreased IL-2
levels (Fig. 3E: po0.05). The decreased IL-2 is suggestive of
diminished proliferation seen in T cells primed with HIV-1-pulsed
MDC. Given that soluble factors, namely TGF-b, released
by Treg type 3 [28], and IL-10, released by type 1 Treg, have the
ability to impair proliferation [28], we were particularly
interested in determining whether their presence decreased
T-cell proliferation in HIV-1-primed cocultures. However, neither
TGF-b nor IL-10 levels were signiﬁcantly affected in the
supernatants (Fig. 3F and G). The unaffected levels of TGF-b/
IL-10 despite HIV-1 presence ruled out the induction of contact-
independent Treg type 3 and Treg type 1 mechanisms. Further,
to rule out any possible cytokine degradation or activity loss
during the 7-day-long priming cultures, we set up transwell
assays whereby HIV-1-primed T cells could constantly supply
factors to the new cocultures. Interestingly, we found that the
ability to impair new DC–T-cell priming was still curtailed when
the cells were separated by a transwell membrane (Fig. 3H).
Taken together, our ﬁndings point to a cell-to-cell contact-
dependent mechanism for the HIV-induced suppression of T-cell
proliferation.
Naturally occurring Treg were not responsible for the
HIV-1-pulsed DC-induced T-cell impairment
Some Treg inhibit T-cell proliferation through secretion of
cytokines, i.e. TGF-b and/or IL-10, whereas others operate
in a contact-dependent manner [29, 30]. Naturally occuring
Treg (nTreg) (CD4
1CD25
1Foxp3
1) exist in all individuals [30]
and play a critical role in chronic HIV-1 infection [31]. Therefore,
we investigated the role of nTreg in the decreased T-cell
proliferation seen in HIV-1-exposed cocultures. To address this,
we depleted the naı ¨ve T cells of nTreg (by removing CD25
1
T cells), before use. Intriguingly, we found that removal of
nTreg failed to restore T-cell proliferation (Fig. 4), indicating
their lack of involvement in promoting T-cell inhibition. Our
results also suggest that priming of naı ¨ve T cells by HIV-1-
exposed DC gives rise to contact-dependent suppressor/Treg that
are distinct from nTreg.
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Figure 2. Presence of both inf-HIV and non-inf HIV impairs the ability of DC to prime naı ¨ve T-cell responses. IDC and MDC were pulsed with
inf-HIV or AT-2 HIV (either HIV-1MN (CXCR4-tropic) or HIV-1BaL (CCR5-tropic)) overnight, washed twice, and cocultured with CFSE-labeled naı ¨ve
bulk T cells at a ratio of 1:10 (10
4 DC and 10
5 T cells). Priming cultures were restimulated with 10000 DC/well after 7 days of coculture and T-cell
proliferation measured on day 8 by CFSE dilution by ﬂow cytometry or by
3H-Thymidine incorporation. (A) HIV-1MN effects on the ability of MDC
and IDC to induce T-cell proliferation (ﬁgure shows one experiment with suppression of T-cell proliferation). Background proliferation with T cells
alone ranged from 3 to 8% depending on the donor. (B) HIV-1BAL effects on the ability of MDC and IDC to induce T-cell proliferation (graph shows
one representative experiment). (A and B) Bars show the mean of three wells per group7SEM. (C and D) Normalized values for assays performed
with CXCR4-tropic HIV-1MN (n58) and CCR5-tropic HIV-1BaL (n520) respectively. p o 0.001, one-way ANOVA non-parametric Tukey’s test.
& 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2010. 40: 2248–2258 Immunomodulation 2251B
o
n ***
40
20
M
 
x
1
0
-
3
)
 
20 A
N
o
r
m
a
l
i
z
e
d
 
T
 
c
e
l
l
 
p
r
o
l
i
f
e
r
a
t
i
o
10
20
30
5
10
15
h
y
m
i
d
i
n
e
 
(
C
P
5
10
15
0
T
Mock
+
Primed 
T cells:
New 
MLR:
AT-2 HIV
+
Inf-HIV
+
-
+
0
H
-
T
Mock
+
Primed 
T cells:
New MLR:
AT-2 HIV
+
Inf-HIV
+
-
+
0
3
Mock
+
AT-2 HIV
+ +
-
+
D
l
i
f
e
r
a
t
i
o
n
 
(
%
)
30
40
50
40
60
80
f
e
r
a
t
i
o
n
(
 
%
) C
Primed 
T cells:
T
 
c
e
l
l
 
p
r
o
-
0
10
20
T cells Mock AT-2 HIV Inf-HIV
0
20
T
 
c
e
l
l
 
p
r
o
l
i
Mock Primed 
T cells:
AT-2 HIV Inf-HIV -
E
New 
MLR: + + + ++
100
*
*
+ New 
MLR:
+ + +
150
F
20
40
60
80
50
100
150
L
-
1
0
 
(
p
g
/
m
l
)
− NS −
None AT-2 HIV Inf-HIV
0
20
N
o
r
m
a
l
i
z
e
d
 
I
L
-
2
 
e
x
p
r
e
s
s
i
o
n
0
I
L
Mock               Inf-HIV
150 H 100
NS G
m
a
l
i
z
e
d
 
T
 
c
e
l
l
 
o
l
i
f
e
r
a
t
i
o
n
50
100
150
40
60
80
G
F
-
ß
 
(
p
g
/
m
l
)
− NS −
N
o
r
m
p
r
o
Mock
+
Primed T cells:
New MLR:
AT-2 HIV
+
Inf-HIV
+
0
50
Culture
media
+
0
20
Mock                  Inf-HIV
T
Figure 3. T cells primed in the presence of CCR5-tropic HIV-1BaL impair T-cell proliferation in new naı ¨ve priming assays in a contact-dependent
manner. (A and B) T cells primed by mock or HIV-1-pulsed MDC were harvested after 8 days, washed, and transferred into new allogeneic
cocultures. The ratio of DC to new naı ¨ve T cell was 1:10 and 1:1 ratio for the primed and new naı ¨ve T cells. T-cell proliferation was measured on
day 7 by
3H-Thymidine incorporation or CFSE dilution. (A) One representative experiment of T cells primed by mock or HIV-1-pulsed MDC.
(B) Normalized values for assays performed (n55). (C) HIV-1-pulsed IDC priming assay (performed as described for (A and B)) with impaired
proliferation. (D) Supernatants were harvested from cultures with mock T cells, mock, AT-2 HIV, or inf-HIV-1-pulsed DC and added to new
allogeneic cocultures. T-cell proliferation was measured on day 7 by ﬂow cytometry (CSFE) (n55). (E) Supernatants harvested on day 8 from four
independent experiments were analyzed by BioPlex IL-2 cytokine assay and results were normalized. (n54). (F–H) Supernatants from day 8
cocultures of naı ¨ve T cells pulsed with mock DC, HIV-1-exposed DC, and mock T cells were assessed for IL-10 (F) and TGF-b (G) by ELISA (n56).
(H) T cells primed by mock MDC, pulsed with AT-2 HIV, or inf-HIV were harvested after 8 days, washed, and cultured in the upper chamber of a
transwell 96-well plate with a new allogeneic DC–T-cell priming culture in the bottom chamber. The ratio of DC to new naı ¨ve T cell in the bottom
chamber was 1:10, (naı ¨ve T-cell numbers equivalent to primed T cells in the upper chamber). T-cell proliferation was measured on day 7 by
3H-Thymidine incorporation and ﬂow cytometry (normalized values (n54)). (A, C, and D) Bars show the mean of three wells per group7SEM.
 p o 0.005 and  po0.001 one-way ANOVA non-parametric Tukey’s test.
& 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2010. 40: 2248–2258 Karlhans F. Che et al. 2252T cells primed in the presence of HIV-1 gave rise to
increased levels of suppressor T cells
In HIV-1-infected individuals, several surface markers are involved in
dampening T-cell responses, such as CTLA-4, [22] PD-1 [32], and
intracellular Foxp3 expression in Treg [31]. Furthermore, TRAIL
expression contributed to T-cell impairment in HIV-infected indivi-
duals [17]. We determined whether T cells primed in the presence of
H I V - 1e x p r e s s e dC T L A - 4 ,P D - 1 ,P D - L 1 ,F o x p 3 ,a n dT R A I La n df o u n d
that there was an increase in PD-1 (8–53%), CTLA-4 (8–40%),
Foxp3 (5–16%), and TRAIL (7–21%) expressions. The corresponding
MFI levels correlated with the percentage of expression (Fig. 5A) on
T cells primed with AT-2 HIV and inf-HIV-exposed DC as compared
with mock DC. Moreover, both CD4
1 and CD8
1 T cells expressed
PD-1 and TRAIL, while CTLA-4 was expressed only on CD4
1 Tc e l l s .
Foxp3 was found mostly on CD4
1 T cells, but lower levels occurred
on some CD8
1 T cells (data not shown). It is worth noting that we
observed none or very low PD-L1 levels on T cells independent of the
culture conditions, whereas both mock and HIV-1-pulsed DC
expressed high PD-L1 levels (data not shown). Signiﬁcant upregula-
tion of PD-1, CTLA-4, TRAIL, and Foxp3 (Fig. 5B) was evident on
T cells primed by HIV-1-exposed DC, which emphasizes the critical
consequences these molecules have on T-cell proliferation.
Decreased activation and CD25
1 levels on T cells
primed in the presence of HIV-1-pulsed DC
Activated T cells express CD25 and require IL-2 for survival and
proliferation. To address this, we stained the primed T cells for
CD25 expression and IL-2 production. Interestingly, there was a
signiﬁcant decrease in CD25 expression (Fig. 6A and B) and IL-2
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PD-1, TRAIL, CTLA-4, or Foxp3 on T cells. (B) Four to six separate
experiments were normalized and statistics performed. p o 0.05,
p o 0.005, p o 0.001, one-way ANOVA non-parametric Tukey’s test.
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which was consistent with decreased T-cell activation observed
under these conditions. As we noticed lower IL-2 and CD25 levels
among the HIV-1-primed T-cells, we tested whether exogenous
IL-2 could rescue T-cell impairment caused by PD-1 or CTLA-4, as
shown by others [33, 34]. The addition of IL-2 induced a slight
increase in the control T cell and mock DC–T-cell culture
proliferations, but had no effect on HIV-1-primed cultures
(Fig. 6C, representative experiments, n53), indicating that
T-cell impairment in HIV-exposed cocultures could not be
salvaged with exogenous IL-2 while the cells were still in contact.
HIV-1-induced suppression was attributed to surface
expression of CTLA-4, PD-1, and TRAIL by T cells
The elevated PD-1, CTLA-4, and TRAIL expression by T cells
primed by HIV-1-pulsed DC could be the source of T-cell
impairment. Therefore, we examined if blocking these molecules
effectively salvaged the ongoing HIV-1-induced T-cell suppres-
sion [22, 32]. We showed that there was a slight increase, but
insigniﬁcant restoration of T-cell proliferation when individual
blocking mAb were used (Fig. 7A). However, a mAb cocktail
against PD-1, CTLA-4, and TRAIL signiﬁcantly restored T-cell
proliferation that ranged from 83% to full recovery (Fig. 7B and
C). Thus, HIV-1 presence during DC priming of naı ¨ve T cells gives
rise to reversible suppressor T cells expressing CTLA-4, PD-1, and
TRAIL that could impair the T-cell activation and proliferation.
Discussion
We demonstrated that HIV-1-exposed DC developed impaired
abilities to prime and activate functional T-cell responses from
naı ¨ve T cells owing to induction of contact-dependent suppressor
T cells (expressing PD-1, CTLA-4, and/or TRAIL), which
originated from the naı ¨ve T-cell pool but not from nTreg. These
ﬁndings may be relevant to the events preceding HIV-1
pathogenesis in vivo, whereby the presence of HIV-1 during the
initiation of immune responses against HIV-1 or other pathogens
within the lymph nodes may signiﬁcantly affect the quality and
magnitude of the immune responses generated. We previously
showed that MDC, when loaded with whole virions, have the
ability to prime HIV-1-speciﬁc CD4
1 and CD8
1 T-cell responses
from HIV-1 naı ¨ve individuals [25], and expand the existing
memory T-cell responses [35]. These studies together with our
ﬁndings indicate that although HIV-1-pulsed DC could prime and
activate antigen-speciﬁc T-cell responses, the existence of diverse
mechanisms could simultaneously positively or negatively inﬂu-
ence ongoing T-cell activation to eventually determine the
immune effectiveness generated.
Treg modulate immune activation to prevent pathological
self-reactivity [28, 36]. Treg develop either from classical naı ¨ve
T cells or from nTreg subsets under particular conditions of
antigen exposure [28] and mediate suppressive functions via
direct cellular interaction or secretion of inhibitory cytokines
[28]. Importantly, contact-independent regulation could involve
participation of immunosuppressive cytokines, i.e. TGF-b and
IL-10 [36, 37]. It is worth noting that some evidence suggest that
IL-10 secretion could result in T-cell impairment induced by
HIV-1 [11]. Nevertheless, we ruled out the involvement of IL-10,
TGF-b, and other secreted factors occurring in culture super-
natants in impairment of T-cell proliferation. Rather, the T cells
primed with HIV-1-pulsed DC, inhibited T-cell proliferation in a
contact-dependent manner, via CTLA-4, PD-1, and TRAIL. Accu-
mulating evidence suggest that reverse signaling in DC after PD-
1-PD-L1 ligation triggers T-cell suppression rather than activation
[38]. Although we did not detect PD-L1 on T-cells, the possible
mechanism could be via a cross-talk with PD-L1 expressing DC.
CTLA-4 is upregulated on activated T cells and expressed by
Treg to ensure tight regulation of T-cell activation. It antagonizes
the signal pathway mediated via CD28 ligation leading to T-cell
inhibition by reduced IL-2 production [39]. A recent study
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HIV-speciﬁc CD4
1 T cells and correlated positively with disease
progression [22]. Our study also observed an upregulation and
coexpression of both CTLA-4 and PD-1 in HIV-1-primed T-cell
cultures. PD-1 is expressed on activated CD4
1 and CD8
1 T cells,
and B cells, suggesting its involvement in a broader spectrum of
immune regulation than CTLA-4, which occurs only on CD4
1
T cells [32].
Previous studies indicated that PD-1 and CTLA-4 interactions
with their respective ligands dampened IL-2 production [33, 34],
which was reversed by the blockade of these receptors or
exogenous addition of IL-2 [34, 40]. Interestingly, we showed
that IL-2 addition failed to overcome the inhibitory mechanisms,
whereas blocking of these receptors restored the T-cell prolif-
eration attributes. This could be due to differences between the
systems used, such as the sustained maintenance of signaling
between DC–T cells and/or the involvement of pathways other
than PD-1 and CTLA-4, e.g. TRAIL has recently been shown to
expand CD4
1 Treg [41] besides its involvement in T-cell apo-
ptosis [42]. Interestingly, others demonstrated that TRAIL could
inhibit antigen-speciﬁc T-cell activation without necessarily
inducing apoptosis by decreasing calcium inﬂux [43]. TRAIL has
two pro-apoptotic death receptors, DR4 and DR5 [15], and three
others that could engage TRAIL without initiating apoptosis [44].
Hence, TRAIL expression in the presence of HIV-1 could directly
induce the T-cell suppression rather than apoptosis, as shown in
our assays.
The mechanisms involved in HIV-1 pathogenesis are complex.
Here, we revealed the effects that HIV-1 can have on the ability of
DC to prime naı ¨ve T cells within lymphoid organs during HIV-1
infection. The HIV-1-induced suppression seen herein seems to
depend on the concerted effects of CTLA-4, PD-1, and TRAIL
signaling as their concurrent neutralization restored T-cell
proliferation. Our ﬁnding ﬁts with the fact that CTLA-4 and
PD-1 ligation induces immunoinhibitory signals attenuating
TCR-mediated IL-2 production and T-cell proliferation [23, 32,
40, 45].
In conclusion, our in vitro ﬁndings showed that the presence
of HIV-1 during the naı ¨ve T-cell activation by DC generates
suppressor T cells expressing PD-1, CTLA-4, TRAIL, and Foxp3.
These molecules were responsible for the T-cell impairment
observed, since their blockade successfully restored T-cell prolif-
eration. The induction of contact-dependent suppressor T cells in
our system could be either a way for the immune system to
control an overload of the system or due to one or several of the
immunomodulatory activities of HIV-1 proteins. It is now clear
that HIV-1 infection could program DC to generate suppressor
T cells. Further studies must be carried out to elucidate the
genetic factors and underlying mechanisms that contribute to the
expression of inhibitory receptors on T cells after HIV-1exposure.
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Culture medium, cytokines, and reagents
RPMI1640 was supplemented with 10mM HEPES (Fisher Scientiﬁc,
Leicestershire, UK), 20mg/mL gentamicin (Fisher Scientiﬁc), 2mM
L-glutamine (Sigma-Aldrich, St. Louis, MO), and 1% plasma (DC
medium) or 5% heat-inactivated pooled human serum (PHS) (5%)
(Fisher Scientiﬁc). Recombinant human GM-CSF (Immunex,
Seattle, WA, USA) (100IU/mL) and recombinant human IL-4
(R&D Minneapolis, MN, USA) (300U/mL).
DC
Buffy coats from healthy donors were purchased from the
transfusion unit at Huddinge Hospital, Stockholm and DC
prepared as described previously [18, 25].
DC maturation was induced by adding 30ng/mL polyI:C (Sigma-
Aldrich) and incubated at 371Ci na5 %C O 2 incubator for 24h.
Flow cytometry
PE-mAb directed against CD83, CD86, CD80, CD14, HLA-DR, and
their corresponding isotype controls IgG1, and IgG2a (BD
Pharmingen, Franklin Lakes, NJ, USA) were used for phenotypic
characterization of DC. Directly conjugated mAb against PD-1
FITC, PD-1L PE, TRAIL-PE, CTLA-4-PE, CD45RO-PECY5,
CD45RA-PECY5, and Foxp3-FITC (BD Pharmingen) were used
for T-cell immunophenotyping before and after the coculture.
Data acquired on a FACSCalibur (BD Immunocytometry Systems,
San Jose, CA, USA) were analyzed using FlowJo software
(TreeStar, Ashland, OR, USA).
Viruses and infection of cells
HIV-1 MN, a CXCR4-tropic clade B virus was produced by
infection of CL.4/CEMX174 (T1) cell line. Propagated viruses
were puriﬁed as described previously [24]. Virus inactivation
with AT-2 (AT2 HIV) was performed as described earlier [46]. Inf
or AT-2 HIV-1MN or HIV-1BaL (175–750ng/mL) was added to
110
5 DC and incubated at 371C for 24h. Cells were washed
twice and used in different assays. Mock DC were used as
controls. The DC viability after infection was determined using
the Annexin V and 0.4% Trypan blue exclusion.
Allogeneic DC–T cell proliferation assay
Naı ¨ve CD4
1 and CD8
1 T cells were negatively selected using
magnetic beads by depleting monocytes (CD14), B cells (CD19),
NK cell, (CD56), and memory T cells (CD45RO) (Miltenyi Biotec,
Auburn, CA, USA) from PBMC. HIV-1-exposed IDC and MDC
were harvested, washed twice, and cocultured in 5% PHS with
CFSE-labeled (Fisher Scientiﬁc) naı ¨ve CD4
1 and CD8
1 T cells at a
ratio of 1:10 (10000 DC:100000 T cells) in 96-well plates (BD
Falcon, Franklin Lakes, NJ, USA). Assays were restimulated once
after 7 days with the same groups of mock, inf-HIV, or AT-2 HIV-
exposed DC utilized to initiate the priming event. T cells were
analyzed 1 day after restimulation. Mock DC–T-cell cocultures
were used as standard to evaluate the effects HIV-1 had on
T-cell priming. T-cell proliferation was assessed at several
time points between days 3 and 11 by CFSE dilution by ﬂow
cytometry and 4mCi of
3H-Thymidine incorporation (Amersham
Pharmacia).
Detection of suppressor/Treg
Day 8 T cells primed by mock, inf-HIV, and AT-2 HIV-exposed
DC were added to new mock allogeneic DC–T-cell cultures. DC
were cocultured with CFSE-labeled naı ¨ve T cells at a ratio
of 1:10. The previously primed T cells were added at a ratio
of 1:1 to the new naı ¨ve CFSE-labeled T cells and proliferation
was monitored. Supernatants or T cells from day 8 cocultures
primed by mock, inf-HIV, and AT-2 HIV-exposed DC, were
added directly to new priming cultures or to the upper
chamber, respectively, of a Transwell-96-well system
containing new priming cultures at the bottom chamber (pore-
size 0.4mm) (Sigma-Aldrich). Proliferation was measured as
described above.
T-cell proliferation assays with added IL-2
Recombinant human IL-2 (150IU/mL) (R&D Systems) was
added to DC–T-cell cocultures and replenished every second
day. The cultures were restimulated after 7 days and T-cell
proliferation was monitored on day 8.
Cytokine measurements
Supernatants from day 8 of cocultures were analyzed by BioPlex
Cytokine Luminex assay for IL-10, IL-2, IL-4, IL-5, IL-13, IL-17,
TNF-a, G-CSF, TGF-b, IFN-g, RANTES, PDGF-b, MCP-1, IP-10,
bFGF, eotaxia, IL-9, IL-8, IL-6, IL-1R-a, VEGF, and IL-1Rb
(BioRad, Hercules, CA, USA). TGF-b and IL-10 were reexamined
individually by ELISA (eBioscience, San Diego, CA, USA).
Proliferation assays with blockade of PD-1, CTLA-4,
and TRAIL
CFSE and
3H-Thymidine assays were performed as described
above. Brieﬂy, the different DC–T-cell cocultures were incubated
with 20mg/mL isotype control antibody (normal-naı ¨ve goat total
& 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2010. 40: 2248–2258 Karlhans F. Che et al. 2256IgG) or anti-human TRAIL/TNFSF10, IgG2b or anti-human PD-1
antibody (R&D), or 20mg/mL of isotype control antibody IgG2ak
(G155–178) or anti-CTLA-4 antibody (BN13; BD). The cultures
were maintained for 7 days in 5% PHS before T-cell proliferation
was measured.
Statistical analysis
We experienced a considerable degree of variability within the
experiments and hence statistic values were obtained by normal-
izing or transforming the data. Each value within a group was
divided by the sum total of values within the group and presented
as percentage. The GraphPad PRISM software (La Jolla, CA, USA)
was used for data analysis using one-way ANOVA nonparametric
Tukey’s test to compare (po0.001, po0.005, po0.05)
between the groups.
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